Roche (OTCMKTS:RHHBY) Lowered to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Roche (OTCMKTS:RHHBY) from a hold rating to a strong sell rating in a research report report published on Tuesday morning,Zacks.com reports.

RHHBY has been the subject of a number of other research reports. HSBC downgraded shares of Roche from a “buy” rating to a “hold” rating in a research report on Monday, July 6th. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective on the stock in a research note on Friday, April 24th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $51.50.

Roche Price Performance

OTCMKTS RHHBY opened at $51.18 on Tuesday. The company’s fifty day simple moving average is $51.32 and its 200-day simple moving average is $52.69. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. Roche has a 52 week low of $37.51 and a 52 week high of $60.85.

Hedge Funds Weigh In On Roche

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OLD National Bancorp IN boosted its position in Roche by 0.7% during the 1st quarter. OLD National Bancorp IN now owns 257,854 shares of the company’s stock worth $12,623,000 after acquiring an additional 1,732 shares during the period. S&CO Inc. increased its holdings in shares of Roche by 163.0% in the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after purchasing an additional 87,107 shares during the period. Opal Capital LLC purchased a new stake in shares of Roche in the first quarter worth approximately $4,448,000. Meritage Portfolio Management purchased a new stake in shares of Roche in the fourth quarter worth approximately $4,372,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Roche by 164.9% during the fourth quarter. Hantz Financial Services Inc. now owns 79,732 shares of the company’s stock worth $4,112,000 after purchasing an additional 49,633 shares during the period.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.